Litigation Details for IMPACT BIOMEDICINES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2023)
✉ Email this page to a colleague
IMPACT BIOMEDICINES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2023)
| Docket | ⤷ Sign Up | Date Filed | 2023-10-23 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | Assigned To | Michael E. Farbiarz | |
| Jury Demand | Referred To | Leda Dunn Wettre | |
| Patents | 10,391,094 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in IMPACT BIOMEDICINES, INC. v. TEVA PHARMACEUTICALS, INC.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for IMPACT BIOMEDICINES, INC. v. TEVA PHARMACEUTICALS, INC. (D.N.J. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-01-25 | 9 | Letter | Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 10,391,094 and 11,400,092. … 4. Until expiration of the Patents-in-Suit, Teva, including any of its successors and…and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third party…parties in connection with any infringement of the Patents-in-Suit by any such third parties in connection…21 C.F.R. § 314.94(a)(12) with respect to the Patents-in-Suit. 9. Nothing herein | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
